Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zejula (Niraparib Tosylate Monohydrate),ZejulaStudy001,2022,USA,MDV,350,62,99,1,27.5,15,85,5,10,30,40,20,60,25,10,5,15,35,50,12,3,2,5,1,20,65,30,Paclitaxel/Carboplatin,Doxorubicin/Cyclophosphamide,Carboplatin/Gemcitabine,Paclitaxel,2,1,1,25,70,40,10,40,50,70,2
Zejula (Niraparib Tosylate Monohydrate),ZejulaStudy002,2023,UK,Claim Database,420,68,98,2,28.1,18,80,7,12,28,38,22,58,27,9,6,13,33,54,14,4,3,6,2,22,63,32,Carboplatin/Docetaxel,FEC,Gemcitabine/Cisplatin,Docetaxel,3,2,2,27,72,42,12,38,50,72,3
Zejula (Niraparib Tosylate Monohydrate),ZejulaStudy003,2023,Germany,MDV,480,65,97,3,26.9,20,75,6,11,29,39,21,59,26,11,4,14,34,52,13,5,1,4,3,21,64,31,Taxol/Carboplatin,EC,Carboplatin/Pemetrexed,Docetaxel/Cyclophosphamide,4,3,3,26,71,41,11,39,50,71,4
Zejula (Niraparib Tosylate Monohydrate),ZejulaStudy004,2024,Canada,Claim Database,300,63,96,4,27.2,17,82,8,9,31,41,19,61,24,12,3,16,36,48,15,2,4,7,1,23,62,33,Carboplatin/Paclitaxel,AC,Pemetrexed/Cisplatin,Cyclophosphamide,5,4,4,28,73,43,13,37,50,73,5
